SPG7 — Spastic Paraplegia 7 (Paraplegin)
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPG7 — Spastic Paraplegia 7 (Paraplegin)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SPG7</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SPG7 — Spastic Paraplegia 7 (Paraplegin)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SPG7" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/heart-failure" style="color:#ef9a9a">Heart Failure</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">70 edges</a></td>
</tr>
</table>
SPG7 (Spastic Paraplegia 7) is a gene located on chromosome 16q24.3 that encodes paraplegin, a mitochondrial-inner-membrane AAA ATPase (ATPases Associated with diverse cellular Activities). Mutations in SPG7 cause a form of autosomal recessive hereditary spastic paraplegia (HSP) characterized by progressive lower limb spasticity, optic atrophy, and often cerebellar ataxia[@casari1998][@martinelli2009].
The gene encodes paraplegin, a 795-amino-acid protein (approximately 88 kDa) that assembles into a 19-subunit m-AAA protease complex embedded in the mitochondrial inner membrane. This complex is essential for mitochondrial protein quality control, mitochondrial dynamics, and respiratory chain assembly. The protein was first linked to neurodegeneration when Casari et al. identified pathogenic mutations in a family with complicated hereditary spastic paraplegia[@casari1998].
SPG7 mutations are among the most common causes of autosomal recessive HSP, accounting for approximately 5-10% of all cases. Over 60 pathogenic variants have been identified, spanning truncating mutations, missense variants, and splice site mutations[@hewamadduma2018].
Gene and Protein Structure
Gene Architecture
The SPG7 gene spans approximately 34 kb and contains 16 exons. The gene encodes paraplegin, a mitochondrial protein with the following structural features:
- N-terminal transmembrane domain: Anchors the protein to the inner mitochondrial membrane with a single transmembrane helix (residues 1-64).
- AAA+ module: The cytosolic domain (residues 65-795) contains the conserved AAA ATPase fold with Walker A and Walker B motifs, the second region of homology (SRH), and the proteolytic active sites organized as a hexameric ring.
- Zinc-binding domain: The proteolytic active sites coordinate zinc ions for protein degradation activity.
The m-AAA Protease Complex
Paraplegin does not function as a standalone protein — it assembles with its close homolog YME1L1 (also known as YME1L) to form the m-AAA protease complex. This complex:
- Resides in the mitochondrial inner membrane with the proteolytic chamber facing the matrix.
- Exhibits both ATP-dependent proteolysis and chaperone activity.
- Assembles as a 19-subunit hetero-oligomer (predominantly paraplegin with variable YME1L1 incorporation).
- Is essential for the degradation of misfolded, misassembled, and obsolete mitochondrial proteins[@warnecke2007][@chan2010].
Evolutionary Context
Paraplegin is highly conserved across eukaryotes, with orthologs in yeast (m-AAA protease subunits mta1 and mta2) and across vertebrates. The AAA module structure places SPG7 in the AAA+ family, which includes FtsH proteases, ClpXP, and other quality control proteases that use ATP hydrolysis to fuel protein unfolding and degradation.
Normal Biological Function
Mitochondrial Protein Quality Control
The primary function of the paraplegin-containing m-AAA protease complex is the ATP-dependent degradation of mitochondrial proteins[@warnecke2007]:
Surveillance: The complex monitors the fidelity of mitochondrial protein import, folding, and assembly.
Degradation of misfolded proteins: Orphaned mitochondrial-encoded proteins (e.g., incompletely assembled complex I subunits) and stress-damaged proteins are targeted for degradation.
Assembly monitoring: Incompletely assembled respiratory chain complexes are recognized and their unincorporated subunits removed.
Regulated proteolysis: The complex degrades specific substrates including OXA1L (inner membrane protein insertase), mitochondrial ribosomal proteins, and letm1 (mitochondrial potassium/hydrogen antiporter)[@atorino2006].Mitochondrial Dynamics
Paraplegin regulates mitochondrial morphology through at least two mechanisms:
Inner membrane fusion: The m-AAA protease degrades subunits of the OPA1 complex that controls cristae remodeling and inner membrane fusion. Loss of paraplegin leads to OPA1 processing alterations and fragmented mitochondria[@kopppen2012].
Cristae maintenance: The structural integrity of mitochondrial cristae depends on paraplegin-mediated regulation of OPA1 and MICOS complex components. Loss of function results in disrupted cristae architecture, particularly in neurons[@nanou2018].Respiratory Chain Assembly and Function
Paraplegin is critical for maintaining respiratory chain complex I (NADH:ubiquinone oxidoreductase) integrity:
- Paraplegin deficiency leads to defective complex I assembly — subunits are synthesized but fail to assemble correctly, resulting in loss of complex I activity.
- Loss of complex I reduces NADH oxidation capacity, increasing ROS production and disrupting cellular energy metabolism.
- Neuronal models show that paraplegin deficiency specifically impairs complex I activity in brain regions with high metabolic demand[@atorino2006].
Brain Expression and Neuronal Relevance
Paraplegin is expressed in all tissues with highest levels in brain, spinal cord, and muscle. Within the nervous system:
- Spinal cord motor neurons: Highest vulnerability — corticospinal tract degeneration drives the spastic paraplegia phenotype.
- Cortical pyramidal neurons: Contribute to occasional cognitive involvement.
- Cerebellar Purkinje cells: Loss explains the cerebellar ataxia seen in many patients.
- Optic nerve: Explains the optic atrophy component.
- Dorsal root ganglia neurons: Relevant to peripheral neuropathy in some patients[@martinelli2009].
Disease Associations
Autosomal Recessive Hereditary Spastic Paraplegia Type 7
The canonical disease caused by SPG7 mutations is autosomal recessive hereditary spastic paraplegia type 7 (SPG7). This is a complicated HSP with both upper motor neuron features (spasticity) and multi-system involvement[@hewamadduma2018].
Epidemiology:
- Accounts for ~5-10% of all autosomal recessive HSP cases
- Prevalence highest in populations with founder mutations (e.g., Spanish, Italian, French-Canadian)
- Age of onset: typically 20-40 years, but ranges from 10 to 60 years
- Both sexes equally affected
Core Clinical Features:
Upper Motor Neuron Involvement:
- Progressive lower limb spasticity (bilateral, symmetric)
- Hypertonia (predominantly extensor)
- Increased deep tendon reflexes
- Bilateral positive Babinski sign
- Bladder dysfunction (urgency, frequency)
- Progressive gait difficulty leading to wheelchair use in ~50% of patients after 20-30 years
Optic Atrophy:
- Present in ~50-60% of patients
- Usually subacute onset in childhood or early adulthood
- Visual acuity decline variable; can range from mild to severe
Cerebellar Ataxia:
- Present in ~30-40% of patients
- Gait and limb ataxia, intention tremor
- Nystagmus in some patients
- Cerebellar atrophy visible on MRI in affected individuals
Additional Features:
- Peripheral neuropathy (20-40%)
- Mild cognitive impairment (variable, often subclinical)
- Tremor (especially cerebellar tremor)
- Dysarthria
- Thin corpus callosum on brain MRI (a hallmark finding)
Genotype-Phenotype Correlation:
- Truncating mutations (nonsense, frameshift) typically cause more severe phenotype with earlier onset
- Missense mutations can produce variable phenotypes, ranging from asymptomatic carriers to classic complicated HSP
- Compound heterozygous missense/insertion-deletion combinations are common
- Some patients carry heterozygous variants and may present with milder, later-onset disease (possible haploinsufficiency or dominant-negative effects)[@hewamadduma2018][@rajakulendran2017]
SPG7 and Movement Disorders
Beyond spastic paraplegia, SPG7 mutations have been associated with:
Bidirectional Chorea: Pfeffer et al. (2017) identified SPG7 mutations in patients presenting with chorea (involuntary movements in both directions), sometimes in combination with spasticity. This expands the phenotypic spectrum of SPG7 beyond pure HSP[@pfeffer2017].
Parkinsonism: Rare reports of SPG7 patients presenting with parkinsonian features (bradykinesia, rigidity, tremor). This may reflect overlap between SPG7-related neurodegeneration and other neurodegenerative movement disorders.
Spastic Ataxia: Some patients present primarily with cerebellar ataxia without prominent spasticity, suggesting a phenotypic continuum between pure HSP and ataxia syndromes.SPG7 and Neurodegeneration
While SPG7 is classically associated with hereditary spastic paraplegia, several lines of evidence suggest broader relevance to neurodegeneration[@noreau2012]:
Overlap with ALS: Mitochondrial dysfunction is central to ALS pathogenesis. SPG7 mutations causing mitochondrial proteostasis defects may sensitize motor neurons to ALS-relevant stressors.
Alzheimer's Disease: Studies have examined SPG7 variants in AD cohorts, with some evidence of association suggesting mitochondrial protein quality control defects may contribute to AD pathogenesis.
Primary Mitochondrial Disease: SPG7 mutations cause complex I deficiency, which is also observed in primary mitochondrial diseases. The mechanistic overlap suggests therapeutic strategies for primary mitochondrial disorders may benefit SPG7 patients.
Unfolded Protein Response: Mitochondrial proteostasis defects activate the mitochondrial unfolded protein response (mtUPR), which may be both protective and damaging depending on context[@pellegrino2017].
Molecular Mechanisms
Pathway Diagram
Mermaid diagram (expand to render)
Mitochondrial Quality Control Pathway
The paraplegin-containing m-AAA protease degrades substrate proteins through an ATP-dependent mechanism:
Substrate recognition (based on misfolding, improper assembly, or targeting signals)
ATP-dependent unfolding of the substrate
Translocation into the proteolytic chamber
Degradation into peptides released into the mitochondrial matrix
Peptides exported via the OPM1/PREPH mitochondrial peptide exporterLoss of paraplegin results in:
- Accumulation of OXA1L fragments, disrupting mitochondrial protein insertion
- Defective assembly of newly synthesized mtDNA-encoded complex I subunits
- Reduced electron transport chain efficiency
- Compensatory mitochondrial proliferation (autophagy/mitophagy defects)
OPA1 Connection
Paraplegin directly processes OPA1, the dynamin-like GTPase controlling inner membrane fusion and cristae junctions. In SPG7-deficient models:
- OPA1 is hyper-processed (excessive cleavage to short forms)
- Long OPA1 (L-OPA1) forms are depleted
- Mitochondrial fusion is reduced
- Cristae become lamellar and disrupted
- The remaining mitochondria are small and fragmented[@kopppen2012]
Diagnostic Approaches
Genetic Testing
- Targeted panel: Sequencing of known HSP genes (SPG7 included in most panels)
- Whole exome sequencing: Increasingly used as first-line; identifies >95% of pathogenic SPG7 variants
- Whole genome sequencing: For cases where exome is negative but clinical suspicion is high (intronic variants possible)
- Sanger sequencing: Confirmatory testing for identified variants; parental testing for segregation
Neuroimaging
- Brain MRI: Thin corpus callosum (characteristic), cerebellar atrophy, white matter changes
- Spinal cord MRI: May show cervical cord atrophy in advanced cases
- MR spectroscopy: Can detect elevated lactate in some patients (complex I deficiency)
Neurophysiology
- Evoked potentials: Visual evoked potentials show delayed P100 in optic atrophy; somatosensory evoked potentials show central conduction delays
- EMG/NCS: Peripheral neuropathy in subset of patients
- Transcranial magnetic stimulation: Shows prolonged central motor conduction times
Biomarkers
- Lactate: Elevated in plasma and CSF in some patients
- Neurofilament light chain (NfL): Elevated in serum/CSF in progressive cases
- Mitochondrial complex I activity: Reduced in fibroblasts (diagnostic support)
Therapeutic Approaches
Current Management
Symptomatic treatment:
- Spasticity: Baclofen (oral or intrathecal), tizanidine, benzodiazepines; botulinum toxin for focal spasticity
- Bladder dysfunction: Anticholinergics (oxybutynin), beta-3 agonists (mirabegron)
- Rehabilitation: Physical therapy (essential), occupational therapy, speech therapy as needed
- Mobility aids: Walking sticks, walkers, wheelchairs as disease progresses
- Optic management: Ophthalmology referral, low vision aids
Genetic counseling: Critical for family planning. Autosomal recessive inheritance means 25% recurrence risk for carrier parents.Emerging Therapies
Gene therapy approaches:
- AAV-mediated SPG7 delivery to motor neurons (preclinical)
- CRISPR-based correction of common variants (early stage)
- Antisense oligonucleotides for splice site mutations (e.g., the c.2869C>T variant)
Mitochondrial-targeted compounds:
- Bezafibrate and similar PPAR agonists: Induce mitochondrial biogenesis pathways, partially compensating for complex I defects
- Rapamycin: May enhance mitophagy and reduce accumulation of damaged mitochondria
- MitoQ and MitoE: Antioxidants targeting mitochondrial ROS
- Epicatechin: Shown to induce mitochondrial biogenesis in cellular models
Protein aggregation inhibitors: Given the mitochondrial proteostasis defect, compounds that enhance chaperone function (e.g., geldanamycin analogs, HSP90 inhibitors) are being explored.
Complex I activity enhancers: Small molecules that stabilize or enhance complex I assembly/function are in development.
Research Gaps and Open Questions
Why motor neurons specifically? Spinal cord motor neurons are preferentially affected despite ubiquitous paraplegin expression. Is this due to their high metabolic demands, unique mitochondrial dynamics, or other cell-intrinsic factors?
Modifier genes: Why do patients with identical SPG7 genotypes have such variable phenotypes? What modifier genes or environmental factors influence severity?
Optic atrophy mechanism: How does paraplegin dysfunction specifically affect the optic nerve? Is it the same mechanism as corticospinal tract degeneration?
Therapeutic window: At what disease stage do interventions need to begin to be effective? Are there presymptomatic biomarkers?
Compound heterozygotes vs homozygous: Are there meaningful phenotypic differences between the two genotypes?
Overlap with primary mitochondrial disease: Should SPG7 be included in mitochondrial disease gene panels?
Animal Models
Spg7 Knockout Mouse
Spg7 knockout mice recapitulate key features of human SPG7:
- Progressive gait abnormalities and hindlimb clasping
- Mitochondrial dysfunction (complex I deficiency)
- Accumulation of OPA1 cleavage products
- Mitochondrial fragmentation in affected tissues
- Optic nerve degeneration
- Corticospinal tract degeneration
Zebrafish and Drosophila Models
Orthologous models show:
- Mitochondrial abnormalities in neurons
- Locomotor defects
- Rescue with wild-type SPG7 expression
These models are being used for drug screening and gene therapy validation.
See Also
- [Hereditary Spastic Paraplegia](/diseases/hereditary-spastic-paraplegia) — disease category
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — core mechanism
- [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics) — OPA1 and cristae connection
- [Complex I Deficiency](/mechanisms/complex-i-deficiency) — respiratory chain involvement
- [Alzheimer's Disease](/diseases/alzheimers-disease) — mitochondrial overlap
- [ALS](/diseases/amyotrophic-lateral-sclerosis) — motor neuron vulnerability overlap
References
[Casari G, et al. Spastic paraplegia and optic atrophy due to mutations in a novel AAA ATPase gene. Cell (1998)](https://pubmed.ncbi.nlm.nih.gov/9635425/)
[Martinelli P, et al. SPG7 mutations cause autosomal recessive hereditary spastic paraplegia. Brain (2009)](https://pubmed.ncbi.nlm.nih.gov/19339257/)
[Hewamadduma C, et al. Genotype-phenotype correlations of SPG7 mutations. Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/30158154/)
[Bento-Abreu A, et al. Altered ribosomal assembly and ribosome biogenesis in SPG7. Hum Mol Genet (2018)](https://pubmed.ncbi.nlm.nih.gov/29796691/)
[Pfeffer G, et al. SPG7 mutations are a common cause of bidirectional chorea. Mov Disord (2017)](https://pubmed.ncbi.nlm.nih.gov/28244937/)
[Lo Giudice M, et al. Molecular genetics of hereditary spastic paraplegia. J Neurol Sci (2014)](https://pubmed.ncbi.nlm.nih.gov/25168231/)
[Noreau A, et al. Association study of SPG7 mutations in neurodegenerative disease. Neurobiol Aging (2012)](https://pubmed.ncbi.nlm.nih.gov/22503075/)
[Wernecke C, et al. The mitochondrial AAA ATPase SPG7/ paraplegin promotes m-AAA protease assembly. J Mol Biol (2007)](https://pubmed.ncbi.nlm.nih.gov/17919528/)
[Atorino L, et al. Loss of m-AAA protease causes complex I deficiency and oxidative stress sensitivity. J Cell Biol (2006)](https://pubmed.ncbi.nlm.nih.gov/17074928/)
[Chan NC, et al. Mitochondrial AAA proteases. FEBS Lett (2010)](https://pubmed.ncbi.nlm.nih.gov/20691611/)
[Rajakulendran S, et al. A heterozygous SPG7 mutation with a novel phenotype. Pract Neurol (2017)](https://pubmed.ncbi.nlm.nih.gov/28137923/)
[Pellegrino MW, et al. Mitochondrial stress and the unfolded protein response. Semin Cell Dev Biol (2017)](https://pubmed.ncbi.nlm.nih.gov/28698034/)
[Köppen M, et al. Mitochondrial dynamics in hereditary spastic paraplegia. Cell Mol Life Sci (2012)](https://pubmed.ncbi.nlm.nih.gov/22648128/)
[Nanou E, et al. Mitochondrial cristae morphology in neurological disease. Neurobiol Dis (2018)](https://pubmed.ncbi.nlm.nih.gov/29630867/)Pathway Diagram
The following diagram shows the key molecular relationships involving SPG7 — Spastic Paraplegia 7 (Paraplegin) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)